ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2730-664X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer ; volume:2 ; number:1 ; day:29 ; month:8 ; year:2022 ; pages:1-9 ; date:12.2022
Communications medicine ; 2, Heft 1 (29.8.2022), 1-9, 12.2022
- Creator
-
Rocconi, Rodney P.
Stanbery, Laura
Tang, Min
Walter, Adam
Monk, Bradley J.
Herzog, Thomas J.
Coleman, Robert L.
Manning, Luisa
Wallraven, Gladice
Horvath, Staci
Bognar, Ernest
Senzer, Neil
Brun, Scott
Nemunaitis, John
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-022-00163-y
- URN
-
urn:nbn:de:101:1-2022111021174148752197
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rocconi, Rodney P.
- Stanbery, Laura
- Tang, Min
- Walter, Adam
- Monk, Bradley J.
- Herzog, Thomas J.
- Coleman, Robert L.
- Manning, Luisa
- Wallraven, Gladice
- Horvath, Staci
- Bognar, Ernest
- Senzer, Neil
- Brun, Scott
- Nemunaitis, John
- SpringerLink (Online service)
Other Objects (12)
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
Rhabdomyosarcoma masquerading as lymphadenopathy in a patient with newly diagnosed Hodgkin’s lymphoma
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
Rhabdomyosarcoma masquerading as lymphadenopathy in a patient with newly diagnosed Hodgkin’s lymphoma
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
Rhabdomyosarcoma masquerading as lymphadenopathy in a patient with newly diagnosed Hodgkin’s lymphoma
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Interstitial photodynamic therapy for newly diagnosed glioblastoma